
Kymera Therapeutics will announce results from its BROADEN2 Phase 2b trial of KT-621, an oral STAT6 degrader for moderate to severe atopic dermatitis, on November 23, 2026. KT-621 targets a key driver of Type 2 inflammation and is also being developed for asthma and other inflammatory diseases. The company aims to offer a new oral treatment option for millions with Type 2 diseases. A webcast and press release will provide full details of the trial outcomes and next steps.
Kymera Therapeutics shares are trading at USD 126.50 on Pluang as of Nov 21, 2026 04:11 WIB. The stock gained 5.96% in one day, showing strong investor interest ahead of the trial results. Its market cap stands at $10.20 billion, reflecting significant market value in the health sector.